L-carnitine and Ginkgo biloba Supplementation In Vivo Ameliorates HCD-Induced Steatohepatitis and Dyslipidemia by Regulating Hepatic Metabolism-Reference-Cited by-同舟云学术

L-carnitine and Ginkgo biloba Supplementation In Vivo Ameliorates HCD-Induced Steatohepatitis and Dyslipidemia by Regulating Hepatic Metabolism

Published:2024-04-23 Issue:9 Volume:13 Page:732
ISSN:2073-4409
Container-title:Cells
language:en
Short-container-title:Cells

Author:

Nofal Amany E.¹^ORCID,AboShabaan Hind S.²^ORCID,Fadda Walaa A.³^ORCID,Ereba Rafik E.⁴^ORCID,Elsharkawy Sherin M.⁵,Hathout Heba M.⁶^ORCID

Affiliation:

1. Zoology Department, Faculty of Science, Menoufia University, Shebin El-Kom 32511, Egypt

2. Clinical Pathology Department, National Liver Institute Hospital, Menoufia University, Shebin El-Kom 32511, Egypt

3. Human Anatomy and Embryology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom 32511, Egypt

4. Department of Pharmacology, Faculty of Medicine, Al-Azhar University, Cario 11511, Egypt

5. Physiology Department, Medicine College, Banha University, Banha 13511, Egypt

6. Natural Resources Department, Faculty of African Postgraduate Studies, Cairo University, Giza 12613, Egypt

Abstract

Treatment strategies for steatohepatitis are of special interest given the high prevalence of obesity and fatty liver disease worldwide. This study aimed to investigate the potential therapeutic mechanism of L-carnitine (LC) and Ginkgo biloba leaf extract (GB) supplementation in ameliorating the adverse effects of hyperlipidemia and hepatosteatosis induced by a high-cholesterol diet (HCD) in an animal model. The study involved 50 rats divided into five groups, including a control group, a group receiving only an HCD, and three groups receiving an HCD along with either LC (300 mg LC/kg bw), GB (100 mg GB/kg bw), or both. After eight weeks, various parameters related to lipid and glucose metabolism, antioxidant capacity, histopathology, immune reactivity, and liver ultrastructure were measured. LC + GB supplementation reduced serum total cholesterol, triglyceride, low-density lipoprotein cholesterol, glucose, insulin, HOMA-IR, alanine transaminase, and aspartate transaminase levels and increased high-density lipoprotein cholesterol levels compared with those in the HCD group. Additionally, treatment with both supplements improved antioxidant ability and reduced lipid peroxidation. The histological examination confirmed that the combination therapy reduced liver steatosis and fibrosis while also improving the appearance of cell organelles in the ultrastructural hepatocytes. Finally, the immunohistochemical analysis indicated that cotreatment with LC + GB upregulated the immune expression of GLP-1 and β-Cat in liver sections that were similar to those of the control animals. Mono-treatment with LC or GB alone substantially but not completely protected the liver tissue, while the combined use of LC and GB may be more effective in treating liver damage caused by high cholesterol than either supplement alone by regulating hepatic oxidative stress and the protein expression of GLP-1 and β-Cat.

Publisher

MDPI AG

Link

https://www.mdpi.com/2073-4409/13/9/732/pdf

Reference106 articles.

1. Metabolic drivers of non-alcoholic fatty liver disease;Bence;Mol. Metab.,2021

2. Wang, J., He, K., Yang, C., Lin, X., Zhang, X., Wang, Y., Liu, G., and Xian, X. (2019). Dietary Cholesterol Is Highly Associated with Severity of Hyperlipidemia and Atherosclerotic Lesions in Heterozygous LDLR-Deficient Hamsters. Int. J. Mol. Sci., 20.

3. Dietary Cholesterol Exacerbates Hepatic Steatosis and Inflammation in Obese LDL Receptor-Deficient Mice;Subramanian;J. Lipid Res.,2011

4. Cholesterol is a Significant Risk Factor for Non-Alcoholic Steatohepatitis;Walenbergh;Expert Rev. Gastroenterol. Hepatol.,2015

5. Immunostimulatory and Anti-Inflammatory Impact of Fragaria Ananassa Methanol Extract in a Rat Model of Cadmium Chloride-Induced Pulmonary Toxicity;Nofal;Front. Immunol.,2023